Invacare Corp. was a giant in home health care equipment. It still is, with some $900 million in annual revenue. But that's down from $1.7 billion at its peak, with a stock price valued at more than $50 per share. In 2004, Spartech Corp. built an injection molding plant in Mexico in part to keep up with demands for wheelchair parts from the Elyria, Ohio-based company.
But as of Sept. 19, each share was selling for about $1. For the first half of 2022, Invacare reported $390 million in sales, a 7.5 percent drop vs. the same period in 2021, and a net loss of $46 million, a whopping 86 percent increase from a year ago.
Jeremy Nobile from our sister paper Crain's Cleveland Business takes a deep dive into what happened to the company and the work to try and restore it.
"No matter how much they restructure or consolidate or how much they drop off products that are not profitable, they just can't seem to make any money," Matt Mishan, an equity research analyst with KeyBanc Capital Markets who has covered Invacare for many years, told Nobile. "It is a story where you have a unique company that is balance sheet insufficient that continues to run into various macro headwinds."